<DOC>
	<DOCNO>NCT01801930</DOCNO>
	<brief_summary>To assess safety tolerability OCV-C02 Patients With Advanced Relapsed Colorectal Cancer Who Are Refractory Intolerant Standard Chemotherapy</brief_summary>
	<brief_title>A Phase 1 Study OCV-C02 Patients With Advanced Relapsed Colorectal Cancer</brief_title>
	<detailed_description>The incidence dose limit toxicity ( DLT ) evaluate cohort six patient start OCV-C02 administration dose level 1 ( OCV-103 OCV-104 0.3 mg ) , increase dose dose level 2 ( 1 mg ) , level 3 ( 3 mg ) , dose level 4 ( 6 mg ) . Once-weekly administration repeat four time treatment cycle , incidence DLT Day 1 Day 29 evaluate . At end Cycle 1 , patient wish continue OCV-C02 treatment provide write consent permit continue participation trial use dose schedule subsequent cycle Cycle 1 .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Patients human leukocyte antigen ( HLA ) A*24:02 Patients histologicallyconfirmed colorectal cancer ( adenocarcinoma ) Patients advance relapsed colorectal cancer refractory intolerant standard chemotherapy Patients Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 time enrollment trial . Patients HIV antibody test positive Patients active infection Patients suspect CNS metastasis colon cancer ( metastatis brain )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>OCV-C02</keyword>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Antigen specific cancer immunotherapeutic</keyword>
</DOC>